Carregando...
Trial design: how must we move ahead?
Scleroderma is clinically heterogeneous and a variety of plausible mechanisms of disease have been hypothesized. Recent years have witnessed a significant improvement in overall survival although all of the gains in management have been therapies for specific organ involvement, e.g. renal crisis and...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2533052/ https://ncbi.nlm.nih.gov/pubmed/18784148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/ken312 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|